Innovent Biologics, Inc. (IVBXF)

Market Cap	10.93B
Revenue (ttm)	1.29B
Net Income (ttm)	-12.96M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	670
Open	5.49
Previous Close	5.97
Day's Range	5.49 - 5.98
52-Week Range	3.91 - 6.40
Beta	0.31
RSI	59.80
Earnings Date	Aug 22, 2025

About Innovent Biologics

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-α monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatini...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5,659
• Stock Exchange: OTCMKTS
• Ticker Symbol: IVBXF

Financial Performance

In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.

Financial numbers in CNY